CN106610406A - Micro-extraction method of honeysuckle - Google Patents
Micro-extraction method of honeysuckle Download PDFInfo
- Publication number
- CN106610406A CN106610406A CN201510705098.5A CN201510705098A CN106610406A CN 106610406 A CN106610406 A CN 106610406A CN 201510705098 A CN201510705098 A CN 201510705098A CN 106610406 A CN106610406 A CN 106610406A
- Authority
- CN
- China
- Prior art keywords
- acid
- column
- honeysuckle
- extraction
- solid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 33
- 241000205585 Aquilegia canadensis Species 0.000 title claims abstract 7
- 238000004853 microextraction Methods 0.000 title description 2
- 238000002414 normal-phase solid-phase extraction Methods 0.000 claims abstract description 34
- 239000003463 adsorbent Substances 0.000 claims abstract description 30
- 239000000843 powder Substances 0.000 claims abstract description 30
- 239000004570 mortar (masonry) Substances 0.000 claims abstract description 17
- 150000007965 phenolic acids Chemical class 0.000 claims abstract description 14
- 239000006228 supernatant Substances 0.000 claims abstract description 13
- 239000003480 eluent Substances 0.000 claims abstract description 11
- 235000009048 phenolic acids Nutrition 0.000 claims abstract description 8
- 239000000945 filler Substances 0.000 claims abstract description 5
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims description 70
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 54
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims description 34
- GWTUHAXUUFROTF-UHFFFAOYSA-N pseudochlorogenic acid Natural products C1C(O)C(O)C(O)CC1(C(O)=O)OC(=O)C=CC1=CC=C(O)C(O)=C1 GWTUHAXUUFROTF-UHFFFAOYSA-N 0.000 claims description 34
- CWVRJTMFETXNAD-NXLLHMKUSA-N trans-5-O-caffeoyl-D-quinic acid Chemical compound O[C@H]1[C@H](O)C[C@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-NXLLHMKUSA-N 0.000 claims description 34
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims description 32
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims description 32
- 229940074393 chlorogenic acid Drugs 0.000 claims description 32
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims description 32
- 235000001368 chlorogenic acid Nutrition 0.000 claims description 32
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims description 32
- 239000013558 reference substance Substances 0.000 claims description 19
- 239000007788 liquid Substances 0.000 claims description 17
- 238000011049 filling Methods 0.000 claims description 11
- 238000001514 detection method Methods 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 7
- 239000007790 solid phase Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 5
- KRZBCHWVBQOTNZ-RDJMKVHDSA-N (3r,5r)-3,5-bis[[(e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]-1,4-dihydroxycyclohexane-1-carboxylic acid Chemical compound O([C@@H]1CC(O)(C[C@H](C1O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 KRZBCHWVBQOTNZ-RDJMKVHDSA-N 0.000 claims description 4
- 238000004458 analytical method Methods 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 238000003801 milling Methods 0.000 claims description 2
- 229930014626 natural product Natural products 0.000 claims description 2
- 238000005070 sampling Methods 0.000 claims description 2
- KRZBCHWVBQOTNZ-UHFFFAOYSA-N (-) 3,5-dicaffeoyl-muco-quinic acid Natural products OC1C(OC(=O)C=CC=2C=C(O)C(O)=CC=2)CC(O)(C(O)=O)CC1OC(=O)C=CC1=CC=C(O)C(O)=C1 KRZBCHWVBQOTNZ-UHFFFAOYSA-N 0.000 claims 3
- UFCLZKMFXSILNL-RVXRWRFUSA-N 4,5-di-O-caffeoylquinic acid Chemical compound O([C@@H]1C[C@](O)(C[C@H]([C@@H]1OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)O)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 UFCLZKMFXSILNL-RVXRWRFUSA-N 0.000 claims 3
- 239000012567 medical material Substances 0.000 claims 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 claims 2
- 239000000470 constituent Substances 0.000 claims 1
- 238000000605 extraction Methods 0.000 abstract description 50
- 229920000858 Cyclodextrin Polymers 0.000 abstract description 45
- 239000001116 FEMA 4028 Substances 0.000 abstract description 30
- 229960004853 betadex Drugs 0.000 abstract description 30
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 abstract description 28
- 235000011175 beta-cyclodextrine Nutrition 0.000 abstract description 28
- 239000004480 active ingredient Substances 0.000 abstract description 27
- 239000000284 extract Substances 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 19
- 238000002222 matrix solid-phase dispersion Methods 0.000 abstract description 18
- 239000000463 material Substances 0.000 abstract description 15
- 238000010828 elution Methods 0.000 abstract description 11
- 238000000227 grinding Methods 0.000 abstract description 9
- 239000003960 organic solvent Substances 0.000 abstract description 9
- 239000007787 solid Substances 0.000 abstract description 3
- 241001570521 Lonicera periclymenum Species 0.000 description 39
- UFCLZKMFXSILNL-BKUKFAEQSA-N 3,4-di-O-caffeoylquinic acid Natural products O[C@H]1C[C@](O)(C[C@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1OC(=O)C=Cc3ccc(O)c(O)c3)C(=O)O UFCLZKMFXSILNL-BKUKFAEQSA-N 0.000 description 26
- KRZBCHWVBQOTNZ-PSEXTPKNSA-N 3,5-di-O-caffeoyl quinic acid Chemical compound O([C@@H]1C[C@](O)(C[C@H]([C@@H]1O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 KRZBCHWVBQOTNZ-PSEXTPKNSA-N 0.000 description 26
- MVCIFQBXXSMTQD-UHFFFAOYSA-N 3,5-dicaffeoylquinic acid Natural products Cc1ccc(C=CC(=O)OC2CC(O)(CC(OC(=O)C=Cc3ccc(O)c(O)c3)C2O)C(=O)O)cc1C MVCIFQBXXSMTQD-UHFFFAOYSA-N 0.000 description 26
- 238000001195 ultra high performance liquid chromatography Methods 0.000 description 26
- UFCLZKMFXSILNL-BBLPPJRLSA-N (-) 4,5-dicaffeoylquinic acid Natural products OC=1C=C(C=CC=1O)C=CC(=O)O[C@@H]1C[C@@](C[C@H]([C@H]1OC(C=CC1=CC(=C(C=C1)O)O)=O)O)(C(=O)O)O UFCLZKMFXSILNL-BBLPPJRLSA-N 0.000 description 25
- UFCLZKMFXSILNL-PSEXTPKNSA-N Isochlorogenic acid b Chemical compound O([C@@H]1C[C@@](O)(C[C@H]([C@H]1OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)O)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 UFCLZKMFXSILNL-PSEXTPKNSA-N 0.000 description 25
- UFCLZKMFXSILNL-UHFFFAOYSA-N NSC 649410 Natural products C=1C=C(O)C(O)=CC=1C=CC(=O)OC1C(O)CC(O)(C(O)=O)CC1OC(=O)C=CC1=CC=C(O)C(O)=C1 UFCLZKMFXSILNL-UHFFFAOYSA-N 0.000 description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 10
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 9
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 7
- 239000000243 solution Substances 0.000 description 6
- 230000008901 benefit Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- CWVRJTMFETXNAD-BMNNCGMMSA-N (1s,3r,4s,5r)-3-[(e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-1,4,5-trihydroxycyclohexane-1-carboxylic acid Chemical compound O[C@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-BMNNCGMMSA-N 0.000 description 3
- 229940097362 cyclodextrins Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- KRZBCHWVBQOTNZ-DLDRDHNVSA-N isochlorogenic acid Natural products O[C@@H]1[C@H](C[C@@](O)(C[C@H]1OC(=O)C=Cc2ccc(O)c(O)c2)C(=O)O)OC(=O)C=Cc3ccc(O)c(O)c3 KRZBCHWVBQOTNZ-DLDRDHNVSA-N 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000012088 reference solution Substances 0.000 description 3
- YZOUYRAONFXZSI-SBHWVFSVSA-N (1S,3R,5R,6R,8R,10R,11R,13R,15R,16R,18R,20R,21R,23R,25R,26R,28R,30R,31S,33R,35R,36R,37S,38R,39S,40R,41S,42R,43S,44R,45S,46R,47S,48R,49S)-5,10,15,20,25,30,35-heptakis(hydroxymethyl)-37,39,40,41,42,43,44,45,46,47,48,49-dodecamethoxy-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,38-diol Chemical compound O([C@@H]([C@H]([C@@H]1OC)OC)O[C@H]2[C@@H](O)[C@@H]([C@@H](O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3O)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O3)O[C@@H]2CO)OC)[C@H](CO)[C@H]1O[C@@H]1[C@@H](OC)[C@H](OC)[C@H]3[C@@H](CO)O1 YZOUYRAONFXZSI-SBHWVFSVSA-N 0.000 description 2
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 2
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000003912 environmental pollution Methods 0.000 description 2
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 2
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KRZBCHWVBQOTNZ-WXAIXHMISA-N 3,5-di-O-caffeoylquinic acid Natural products O[C@@H]1[C@H](C[C@](O)(C[C@@H]1OC(=O)C=Cc2ccc(O)c(O)c2)C(=O)O)OC(=O)C=Cc3ccc(O)c(O)c3 KRZBCHWVBQOTNZ-WXAIXHMISA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-GMZLATJGSA-N 5-Caffeoyl quinic acid Natural products O[C@H]1C[C@](O)(C[C@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-GMZLATJGSA-N 0.000 description 1
- -1 C18 Chemical compound 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- 241000193171 Clostridium butyricum Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000035859 Drug effect increased Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 244000167230 Lonicera japonica Species 0.000 description 1
- 235000017617 Lonicera japonica Nutrition 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000731 choleretic agent Substances 0.000 description 1
- 230000001989 choleretic effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 208000003512 furunculosis Diseases 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000001334 liquid-phase micro-extraction Methods 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- FKHIFSZMMVMEQY-UHFFFAOYSA-N talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了一种由β-环糊精作为基质固相分散萃取技术的吸附剂用于提取检测金银花药材中酚酸类有效成分的方法。所述方法为:取金银花药材粉末和β-环糊精吸附剂加入研钵中研磨,取固相萃取小柱,底部加入筛板,用研磨好的固体填充小柱,将填料填实后顶部再加入筛板,将填好的小柱置于固相萃取仪上,取洗脱剂,注入小柱内,对小柱进行洗脱,底部用离心管收集洗脱液,洗脱结束后,将离心管内洗脱液涡旋、离心,取上层清液即为金银花酚酸类有效成分提取液。本发明所用方法相比传统的提取方法步骤更为简洁快速,省时省力,有机溶剂用量大大减少,提取效果显著,可有效地提取金银花中的酚酸类成分。
The invention discloses a method for extracting and detecting phenolic acid active components in honeysuckle medicinal materials by using β-cyclodextrin as the adsorbent of the matrix solid phase dispersion extraction technology. The method is as follows: take honeysuckle medicinal material powder and β-cyclodextrin adsorbent and add them to a mortar for grinding, take a solid phase extraction column, add a sieve plate at the bottom, fill the column with the ground solid, fill the filler and then top the column Then add the sieve plate, put the filled column on the solid-phase extraction apparatus, take the eluent, inject it into the column, and elute the column, and collect the eluent with a centrifuge tube at the bottom. After the elution, The eluate in the centrifuge tube is vortexed and centrifuged, and the supernatant is taken to be the active ingredient extract of honeysuckle phenolic acids. Compared with the traditional extraction method, the method used in the invention has simpler and quicker steps, saves time and labor, greatly reduces the amount of organic solvents, has remarkable extraction effect, and can effectively extract the phenolic acid components in the honeysuckle.
Description
技术领域technical field
本发明属于天然药物提取检测领域。它涉及一种药用植物的微量提取方法,具体地说,它涉及由β-环糊精作为吸附剂,结合微量基质固相分散萃取技术,用来提取金银花中酚酸类有效成分的新方法。The invention belongs to the field of extraction and detection of natural medicines. It relates to a micro-extraction method of medicinal plants, specifically, it involves the use of β-cyclodextrin as an adsorbent, combined with micro-matrix solid-phase dispersion extraction technology, a new method for extracting the active components of phenolic acids in honeysuckle .
背景技术Background technique
金银花为忍冬科植物忍冬(Lonicera japonica Thunb.)的干燥花蕾或带初开的花。金银花具有清热解毒,疏散风热的作用。用于痈肿疔疮,喉痹,丹毒,热毒血痢,风热感冒,温病发热等。绿原酸(chlorogenic acid)、新绿原酸(neochlorogenic acid)、异绿原酸(isochlorogenic acid)是金银花的主要活性成分。异绿原酸是一混合物,而3,5-二咖啡酰奎宁酸(3,5-O-dicaffeoylquinic acid)与4,5-二咖啡酰奎宁酸(4,5-O-dicaffeoylquinic acid)为其主要成分。据报道,绿原酸类化合物具有抗菌、利胆、止血、增加白血球等药理作用。并且有显著增强胃肠蠕动和促进胃液分泌的药理作用。其中含量最高的为绿原酸,其次是3,5-二咖啡酰奎宁酸,4,5-二咖啡酰奎宁酸和新绿原酸。Honeysuckle is the dry flower bud or the first flower of Lonicera japonica Thunb. Honeysuckle has heat-clearing and toxic substances removing, the effect of evacuating wind-heat. For carbuncle swollen furunculosis, sore throat, erysipelas, pyretic toxin blood dysentery, wind-heat cold, fever due to febrile disease, etc. Chlorogenic acid (chlorogenic acid), neochlorogenic acid (neochlorogenic acid), isochlorogenic acid (isochlorogenic acid) are the main active ingredients of honeysuckle. Isochlorogenic acid is a mixture, and 3,5-dicaffeoylquinic acid (3,5-O-dicaffeoylquinic acid) and 4,5-dicaffeoylquinic acid (4,5-O-dicaffeoylquinic acid) as its main ingredient. According to reports, chlorogenic acid compounds have pharmacological effects such as antibacterial, choleretic, hemostasis, and increase of white blood cells. And it has the pharmacological effect of significantly enhancing gastrointestinal motility and promoting gastric juice secretion. Chlorogenic acid has the highest content, followed by 3,5-dicaffeoylquinic acid, 4,5-dicaffeoylquinic acid and neochlorogenic acid.
传统的中药提取方法有浸渍法、渗流法、回流法等,它们普遍具有有机溶剂用量大、提取时间较长、操作过程繁琐、提取率低等缺点。而且这些方法容易损失有效成分,产生较大的误差,大量有机溶剂的使用对身体健康影响较大,且对环境有较大的污染,不符合绿色化学的倡议。固相萃取(Solid-Phase Extraction,SPE)是近年发展起来的一种样品预处理技术,主要用于样品的分离、纯化和浓缩,相比传统的方法可以提高分析物的回收率,使分析物与干扰组分得到有效的分离,减少样品预处理过程,操作简单快速。广泛应用在医药、环境、食品、商检等领域。但它也有有机溶剂用量大、重复性差,易堵塞,流量低,截面积小等缺点。Traditional Chinese medicine extraction methods include dipping method, percolation method, reflux method, etc. They generally have the disadvantages of large amount of organic solvent, long extraction time, cumbersome operation process, and low extraction rate. Moreover, these methods are easy to lose active ingredients and produce large errors. The use of a large amount of organic solvents has a greater impact on health and has greater pollution to the environment, which does not meet the green chemistry initiative. Solid-phase extraction (Solid-Phase Extraction, SPE) is a sample pretreatment technology developed in recent years, which is mainly used for the separation, purification and concentration of samples. Compared with traditional methods, it can improve the recovery rate of analytes and make analytes It can be effectively separated from interfering components, reducing the sample pretreatment process, and the operation is simple and fast. Widely used in medicine, environment, food, commodity inspection and other fields. However, it also has the disadvantages of large amount of organic solvent, poor repeatability, easy clogging, low flow rate, and small cross-sectional area.
鉴于上述局限,许多新的提取方法在固相萃取的基础上发展了起来,主要包括基质固相分散萃取、分子印迹固相萃取、分散液相微萃取、磁性固相萃取等。相比传统的固相萃取方法这类新型的萃取方法有更显著的优势,主要有有机溶剂用量少、对环境污染小、操作简单快速、提取效率高。其中基质固相分散萃取技术就颇具代表性。In view of the above limitations, many new extraction methods have been developed on the basis of solid phase extraction, mainly including matrix solid phase dispersion extraction, molecular imprinted solid phase extraction, dispersive liquid phase microextraction, magnetic solid phase extraction, etc. Compared with the traditional solid-phase extraction method, this new type of extraction method has more significant advantages, mainly including less organic solvent consumption, less environmental pollution, simple and fast operation, and high extraction efficiency. Among them, the matrix solid phase dispersion extraction technology is quite representative.
基质分散固相萃取(MSPD,matrix solid-phase dispersion)是美国Louisiana州立大学的Barker教授在1989年建立的一种快速样品处理技术。其原理是将固相吸附剂与样品一起研磨,得到半干状态的混合物并将其作为填料装柱,然后用不同的溶剂淋洗柱子,将各种待测物洗脱下来。它将样品的均化、提取、浓缩和净化一步完成,避免了样品在均化、提取、净化等过程中造成的被测物的损失,同时使样品的预处理变的简便,提高了分析速度,减少了有机溶剂的消耗,得到的提取液大都可直接分析检测,减少了操作步骤和对环境的污染。目前针对天然产物的基质固相分散萃取技术的文献报道中,其药材、吸附剂以及洗脱剂的用量都较大,既浪费材料又对环境造成很大的污染。Matrix solid-phase extraction (MSPD, matrix solid-phase dispersion) is a rapid sample processing technology established in 1989 by Professor Barker of Louisiana State University in the United States. The principle is to grind the solid-phase adsorbent with the sample to obtain a semi-dry mixture and pack it into the column as a filler, then rinse the column with different solvents to elute various analytes. It completes the homogenization, extraction, concentration and purification of the sample in one step, avoiding the loss of the analyte caused by the homogenization, extraction and purification of the sample, and at the same time making the pretreatment of the sample easier and improving the analysis speed , reducing the consumption of organic solvents, most of the obtained extracts can be directly analyzed and detected, reducing the operation steps and environmental pollution. In the current literature reports on the matrix solid phase dispersion extraction technology for natural products, the amount of medicinal materials, adsorbents and eluents is relatively large, which not only wastes materials but also causes great pollution to the environment.
基质固相分散萃取的一个关键步骤是吸附剂的选择,目前,用于基质固相分散萃取的吸附剂主要包括硅胶,C18,活性炭,氧化铝,弗罗里硅土等。A key step in matrix solid-phase dispersive extraction is the selection of adsorbents. At present, the adsorbents used for matrix solid-phase dispersive extraction mainly include silica gel, C18, activated carbon, alumina, florisil, etc.
1891年,Villier首先从Bacillus amylobacter作用过的土豆淀粉里分离出环糊精。环糊精(Cyclodextyin,CD)是由环糊精葡萄糖残基转移酶作用于淀粉、糖原、麦芽寡聚糖等葡萄糖聚合物而形成的,由6-12个D-吡喃葡萄糖基以α-1,4-葡萄糖苷键连接而成的环状低聚糖。常见的主要有环糊精α、β、γ三种。其中β-环糊精价廉易得,应用最广,它具有“内腔疏水,外壁亲水”的特殊结构和性质,并在外型上呈“截顶圆锥”状,因此可以于水相中模拟酶的疏水口袋,与一系列有机分子形成包结络合物,广泛应用于环境污染物的吸附和萃取、水不溶性药物分子的包结和增溶、超分子仿酶体系的设计与构筑等领域。而且β-环糊精空腔大小适中,包合能力强,在人体内能被吸收、分解,对人体安全无毒,因此适合作为基质固相分散萃取的吸附剂。In 1891, Villier first isolated cyclodextrin from potato starch treated with Bacillus amylobacter. Cyclodextrin (Cyclodextrin, CD) is formed by the action of cyclodextrin glucose residue transferase on starch, glycogen, maltooligosaccharides and other glucose polymers. - Cyclic oligosaccharides linked by 1,4-glucosidic bonds. The common ones are cyclodextrin α, β, and γ. Among them, β-cyclodextrin is cheap and easy to obtain, and is the most widely used. It has a special structure and properties of "hydrophobic in the inner cavity and hydrophilic in the outer wall", and has a "truncated cone" shape in appearance, so it can be used in the water phase. It simulates the hydrophobic pocket of enzymes and forms inclusion complexes with a series of organic molecules. It is widely used in the adsorption and extraction of environmental pollutants, the inclusion and solubilization of water-insoluble drug molecules, the design and construction of supramolecular enzyme imitation systems, etc. field. Moreover, β-cyclodextrin has a moderate cavity size, strong inclusion ability, can be absorbed and decomposed in the human body, and is safe and non-toxic to the human body, so it is suitable as an adsorbent for matrix solid phase dispersion extraction.
截止目前,以β-环糊精作为吸附剂应用于基质固相分散萃取技术,在提取领域尚未见报道,该方法对于金银花的提取检测更是一片研究空白。So far, β-cyclodextrin has been used as an adsorbent in matrix solid-phase dispersion extraction technology, but there is no report in the field of extraction, and this method is a blank for the extraction and detection of honeysuckle.
发明内容Contents of the invention
本发明是要解决现有基质固相分散萃取技术存在吸附剂选择性少、药材和吸附剂用量大、有机溶剂消耗量大的问题,而提供的利用β-环糊精作为吸附剂,微量基质固相分散萃取金银花药材中有效成分的方法。β-环糊精作为吸附剂与金银花药材中的目标分子吸附结合,使目标分子从药材粉末中快速提取、洗脱,且本发明在一个微量体系中实施,相比药典的提取方法,大大减少了有机溶剂的使用量。The present invention aims to solve the problems of low selectivity of adsorbents, large amount of medicinal materials and adsorbents, and large consumption of organic solvents existing in the existing matrix solid-phase dispersion extraction technology. A method for solid-phase dispersion extraction of effective components in honeysuckle medicinal materials. β-cyclodextrin is used as an adsorbent to adsorb and combine target molecules in honeysuckle medicinal materials, so that target molecules can be quickly extracted and eluted from medicinal material powders, and the present invention is implemented in a trace system, which greatly reduces the the amount of organic solvent used.
本发明采用的技术方案是:The technical scheme adopted in the present invention is:
一种提取金银花药材中酚酸类有效成分的方法,所述酚酸类有效成分为新绿原酸、绿原酸、3,5-二咖啡酰奎宁酸、4,5-二咖啡酰奎宁酸中的一种或两种以上,所述方法包括以下步骤:A method for extracting active ingredients of phenolic acids in honeysuckle medicinal materials, wherein the effective ingredients of phenolic acids are neochlorogenic acid, chlorogenic acid, 3,5-dicaffeoylquinic acid, and 4,5-dicaffeoylquinic acid One or more than two kinds of acid, the method comprises the following steps:
称取金银花样品,置于研钵中,加入环糊精固相萃取填料,与药材样品充分混合研磨。另取固相萃取小柱,底部加入筛板,用研磨好的粉末填充小柱,将填料填实后顶部再加入筛板,将填好的小柱置于固相萃取仪上,对小柱进行洗脱,底部用离心管收集洗脱液,离心,取上层清液即为酚酸类有效成分提取液,用超高效液相色谱仪检测分析。Weigh the honeysuckle sample, put it in a mortar, add cyclodextrin solid-phase extraction filler, mix and grind with the medicinal material sample thoroughly. Take another solid-phase extraction column, add a sieve plate to the bottom, fill the column with ground powder, fill the filler and then add a sieve plate to the top, and place the filled column on the solid-phase extraction apparatus. Carry out elution, collect the eluate with a centrifuge tube at the bottom, centrifuge, take the supernatant to be the active ingredient extract of phenolic acids, and use ultra-high performance liquid chromatography to detect and analyze.
所述环糊精的种类为:α-环糊精,β-环糊精,γ-环糊精,甲基-β-环糊精,二羟丙基-β-环糊精,优选为β-环糊精。The types of cyclodextrins are: α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, methyl-β-cyclodextrin, dihydroxypropyl-β-cyclodextrin, preferably β-cyclodextrin - Cyclodextrins.
所述金银花粉末与β-环糊精吸附剂的质量比为1∶0.25~4,优选为1∶3.The mass ratio of the honeysuckle powder to the β-cyclodextrin adsorbent is 1:0.25~4, preferably 1:3.
所述研磨时间为60~160s,优选为120s。The grinding time is 60-160s, preferably 120s.
所述洗脱剂的种类有:甲醇,80%甲醇水,90%甲醇水,乙腈,乙醇,甲醇:乙醇1∶1,优选为80%甲醇水。The types of eluents include: methanol, 80% methanol water, 90% methanol water, acetonitrile, ethanol, methanol:ethanol 1:1, preferably 80% methanol water.
优选后的具体实验操作步骤为:The specific experimental operation steps after optimization are:
称取金银花药材粉末25mg、按照质量比1∶3称取β-环糊精75mg,加入研钵中研磨120s,取1mL规格固相萃取小柱,底部加入筛板,用研磨好的粉末填充小柱,填实后顶部再加入筛板,将填好的小柱置于固相萃取仪上,取0.5mL80%甲醇水,对小柱进行洗脱,底部用1.5mL规格离心管收集洗脱液,后放入离心仪中,13000rpm离心5min,取上层清液即为酚酸类有效成分提取液,装入进样瓶,用超高效液相色谱仪(UPLC)采样分析,得到提取液的液相色谱图;Weigh 25 mg of honeysuckle herb powder and 75 mg of β-cyclodextrin according to the mass ratio of 1:3, put them into a mortar and grind for 120 seconds, take a 1 mL solid-phase extraction cartridge, add a sieve plate to the bottom, and fill the cartridge with the ground powder. After filling the column, add a sieve plate to the top, place the filled column on a solid-phase extraction apparatus, take 0.5mL80% methanol water, and elute the column, and use a 1.5mL centrifuge tube to collect the eluate at the bottom , then put it into a centrifuge, centrifuge at 13000rpm for 5min, take the supernatant, which is the phenolic acid active ingredient extract, put it into a sample bottle, and use ultra-high performance liquid chromatography (UPLC) for sampling and analysis to obtain the liquid extract of the extract. phase chromatogram;
然后用新绿原酸的对照品配制一系列不同浓度的对照品溶液,按金银花提取液的同样条件用超高效液相色谱仪检测,获得新绿原酸对照品的液相色谱图,以新绿原酸对照品的浓度为横坐标,以新绿原酸对照品色谱峰的峰面积为纵坐标绘制新绿原酸的标准曲线,按同样方法制作绿原酸标准曲线、3,5-二咖啡酰奎宁酸标准曲线,4,5-二咖啡酰奎宁酸标准曲线;根据提取液的液相色谱图中各色谱峰的峰面积及各成分的标准曲线,计算得到提取液中新绿原酸、绿原酸、3,5-二咖啡酰奎宁酸、4,5-二咖啡酰奎宁酸的含量,可相应换算得到提取液中提取的有效成分相对于金银花药材粉末的含量。Then use the reference substance of neochlorogenic acid to prepare a series of reference substance solutions with different concentrations, and detect it with an ultra-high performance liquid chromatography under the same conditions as the extract of honeysuckle to obtain the liquid chromatogram of the reference substance of neochlorogenic acid. The concentration of the reference substance is the abscissa, and the peak area of the chromatographic peak of the new chlorogenic acid reference substance is the ordinate to draw the standard curve of the new chlorogenic acid, and the same method is used to make the chlorogenic acid standard curve, 3,5-dicaffeoylquinic acid Standard curve, 4,5-dicaffeoylquinic acid standard curve; according to the peak area of each chromatographic peak in the liquid chromatogram of the extract and the standard curve of each component, the neochlorogenic acid and chlorogenic acid in the extract are calculated. , 3,5-dicaffeoylquinic acid, and 4,5-dicaffeoylquinic acid content can be converted accordingly to obtain the content of the active ingredients extracted in the extract relative to the honeysuckle powder.
本发明的优点在于:The advantages of the present invention are:
本方法首次采用β-环糊精作为基质固相分散萃取的吸附剂来对中药材进行提取检测,具有独创性,在目前的文献资料中均未见报道。This method is the first to use β-cyclodextrin as the adsorbent of matrix solid-phase dispersion extraction to extract and detect Chinese herbal medicines, which is original and has not been reported in the current literature.
本方法是在微量体系下进行提取检测,相比中国药典所述的提取方法显著减少了有机溶剂的使用,减少了对环境的污染。此外,药材、吸附剂的使用量也极低,节约了资源的同时也提高了环境保护效益。The method carries out extraction and detection under the trace system, and compared with the extraction method described in the Chinese Pharmacopoeia, the use of organic solvents is significantly reduced, and the pollution to the environment is reduced. In addition, the use of medicinal materials and adsorbents is also extremely low, which saves resources and improves environmental protection benefits.
本发明所述的吸附剂环糊精具有“内腔疏水,外壁亲水”的特殊结构和性质,并在外型上呈“截顶圆锥”状,因此吸附萃取效率高、而且β-环糊精空腔大小适中,包合能力强,在人体内能被吸收、分解,对人体安全无毒,不污染环境且廉价易得。使得实验操作环境安全可靠,在倡导绿色化学的今天,符合可持续发展和环境友好理念。The adsorbent cyclodextrin of the present invention has the special structure and properties of "hydrophobic in the inner cavity and hydrophilic in the outer wall", and has a "truncated cone" shape in appearance, so the adsorption and extraction efficiency is high, and β-cyclodextrin The cavity is moderate in size, strong in inclusion ability, can be absorbed and decomposed in the human body, is safe and non-toxic to the human body, does not pollute the environment, and is cheap and easy to obtain. It makes the experimental operation environment safe and reliable, and is in line with the concept of sustainable development and environmental friendliness in today's advocacy of green chemistry.
本发明方法具备一系列优异突出的特性:对人体无毒、不污染环境;操作环境安全可靠;对于天然药物的提取,本发明还具有效率高、操作步骤快速便捷等优点。The method of the present invention has a series of outstanding characteristics: non-toxic to human body, non-polluting environment; safe and reliable operating environment; for the extraction of natural medicines, the present invention also has the advantages of high efficiency, quick and convenient operation steps, and the like.
附图说明Description of drawings
图1为本发明基质固相分散萃取方法的工艺流程图。Fig. 1 is the process flow diagram of the matrix solid phase dispersion extraction method of the present invention.
图2为考察吸附剂种类的基质固相分散萃取效果柱状图。图中,1、2、3、4代表金银花中不同的有效成分,1:新绿原酸、2:绿原酸、3:3,5-二咖啡酰奎宁酸、4:4,5-二咖啡酰奎宁酸。Figure 2 is a histogram of the matrix solid-phase dispersion extraction effect for investigating the types of adsorbents. In the figure, 1, 2, 3, 4 represent different active ingredients in honeysuckle, 1: neochlorogenic acid, 2: chlorogenic acid, 3: 3,5-dicaffeoylquinic acid, 4: 4,5-di Caffeoylquinic acid.
图3为考察药材和β-环糊精之间不同质量比例下的基质固相分散萃取效果柱状图。图中,1、2、3、4分别代表金银花中不同的有效成分,1:新绿原酸、2:绿原酸、3:3,5-二咖啡酰奎宁酸、4:4,5-二咖啡酰奎宁酸。图中横坐标代表β-环糊精的质量,单位mg。Figure 3 is a histogram of the matrix solid phase dispersion extraction effect under different mass ratios between medicinal materials and β-cyclodextrin. In the figure, 1, 2, 3, and 4 respectively represent different active ingredients in honeysuckle, 1: neochlorogenic acid, 2: chlorogenic acid, 3: 3,5-dicaffeoylquinic acid, 4: 4,5- Dicaffeoylquinic acid. The abscissa in the figure represents the mass of β-cyclodextrin in mg.
图4为考察洗脱剂种类的基质固相分散萃取效果柱状图。图中,1、2、3、4分别代表金银花中不同的有效成分,1:新绿原酸、2:绿原酸、3:3,5-二咖啡酰奎宁酸、4:4,5-二咖啡酰奎宁酸。Figure 4 is a histogram of the solid phase dispersion extraction effect of the matrix to investigate the type of eluent. In the figure, 1, 2, 3, and 4 respectively represent different active ingredients in honeysuckle, 1: neochlorogenic acid, 2: chlorogenic acid, 3: 3,5-dicaffeoylquinic acid, 4: 4,5- Dicaffeoylquinic acid.
图5为考察不同研磨时间的基质固相分散萃取效果折线图。图中,1、2、3、4分别代表金银花中不同的有效成分,1:新绿原酸、2:绿原酸、3:3,5-二咖啡酰奎宁酸、4:4,5-二咖啡酰奎宁酸。图中横坐标代表研磨时间。Fig. 5 is a line chart for investigating the effect of matrix solid phase dispersion extraction with different grinding times. In the figure, 1, 2, 3, and 4 respectively represent different active ingredients in honeysuckle, 1: neochlorogenic acid, 2: chlorogenic acid, 3: 3,5-dicaffeoylquinic acid, 4: 4,5- Dicaffeoylquinic acid. The abscissa in the figure represents the milling time.
图6为金银花混合对照品的液相色谱图。图中,1、2、3、4分别代表金银花中不同的有效成分,1:新绿原酸、2:绿原酸、3:3,5-二咖啡酰奎宁酸、4:4,5-二咖啡酰奎宁酸。Fig. 6 is the liquid chromatogram of honeysuckle mixed reference substance. In the figure, 1, 2, 3, and 4 respectively represent different active ingredients in honeysuckle, 1: neochlorogenic acid, 2: chlorogenic acid, 3: 3,5-dicaffeoylquinic acid, 4: 4,5- Dicaffeoylquinic acid.
图7为金银花酚酸类有效成分提取液的液相色谱图。图中,1、2、3、4代表金银花中的有效成分,依次为:1:新绿原酸、2:绿原酸、3:3,5-二咖啡酰奎宁酸、4:4,5-二咖啡酰奎宁酸。Fig. 7 is a liquid chromatogram of the extract solution of active ingredients of honeysuckle phenolic acids. In the figure, 1, 2, 3, and 4 represent the active ingredients in honeysuckle, in order: 1: neochlorogenic acid, 2: chlorogenic acid, 3: 3,5-dicaffeoylquinic acid, 4: 4, 5 - Dicaffeoylquinic acid.
具体实施方式detailed description
通过以下实例来对本发明所提供的检测方法进行更为详细的描述。由于其应用范围广,故具体实施方案也多,下面将结合几个实例的讨论对本发明的内容作进一步的阐述。The detection method provided by the present invention is described in more detail through the following examples. Because of its wide range of applications, there are many specific implementations. The content of the present invention will be further elaborated below in conjunction with the discussion of several examples.
金银花对照品溶液的制备方法具体步骤为:取新绿原酸、绿原酸、3,5-二咖啡酰奎宁酸、4,5-二咖啡酰奎宁酸的对照品适量,精密称定,置棕色量瓶中,加甲醇制成每1mL含新绿原酸500μg、绿原酸500μg、3,5-二咖啡酰奎宁酸500μg、4,5-二咖啡酰奎宁酸500μg的对照品溶液,即得。The specific steps of the preparation method of honeysuckle reference substance solution are: take neochlorogenic acid, chlorogenic acid, 3,5-dicaffeoylquinic acid, 4,5-dicaffeoylquinic acid reference substance amount, accurately weighed, Put it in a brown measuring bottle, add methanol to make a reference solution containing 500 μg of neochlorogenic acid, 500 μg of chlorogenic acid, 500 μg of 3,5-dicaffeoylquinic acid, and 500 μg of 4,5-dicaffeoylquinic acid per 1 mL , that is.
实施例1Example 1
称取5份金银花药材粉末各25mg分别加入5组研钵中,并称取不同种类的环糊精(α-环糊精,β-环糊精,γ-环糊精,甲基-β-环糊精,二羟丙基-β-环糊精)各25mg,加入5组研钵中与金银花药材粉末研磨120s。取5支1mL规格固相萃取小柱,底部均加入筛板,分别用研磨好的粉末填充小柱,填实后顶部均加入筛板,置于固相萃取仪上。取0.5mL甲醇,注入小柱内,对小柱逐一进行洗脱。底部分别用5个1.5mL规格离心管收集,后放入离心仪中,13000rpm离心5min。取上层清液,即为金银花中酚酸类有效成分提取液,分别取样用超高效液相色谱仪(UPLC)采样分析。Weighed 5 parts of honeysuckle herb powder, 25 mg each, and added them to 5 groups of mortars respectively, and weighed different types of cyclodextrins (α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, methyl-β-cyclodextrin, Cyclodextrin, dihydroxypropyl-β-cyclodextrin) 25mg each, added to 5 sets of mortars and ground with honeysuckle powder for 120s. Take five 1mL solid-phase extraction cartridges, add sieves to the bottom, fill the cartridges with ground powder respectively, add sieves to the top after filling, and place them on the solid-phase extraction apparatus. Take 0.5mL of methanol, inject it into the small column, and elute the small column one by one. The bottoms were collected with five 1.5mL centrifuge tubes, and then placed in a centrifuge, centrifuged at 13000rpm for 5min. The supernatant was taken, which was the extract of phenolic acid active ingredients in Flos Lonicerae, and samples were taken and analyzed by ultra-high performance liquid chromatography (UPLC).
实施例所用仪器为安捷伦超高效液相色谱系统(Agilent 1290 Infinity LC,Agilent Technologies,Santa Clara,CA,USA)配备真空抽气泵,二元泵流动相系统,恒温自动进样器,恒温柱温箱。色谱柱:Agilent Zorbax Extend-C18 column(2.1mm×50mm,1.8μm),检测波长:330nm。柱温:40℃。进样量:1μL。流速0.4mL/min,流动相:A:0.1v%甲酸水,B:甲醇。梯度洗脱:0~2min,0%~30%B;2~3min,30%~35%B;3~4min,35%~40%B;4~7min,40%~50%B;7~8min,50%~100%B;8~9min,100%~100%B;9~10min,100%~30%B,平衡时间5min。The instrument used in the embodiment is an Agilent ultra-high performance liquid chromatography system (Agilent 1290 Infinity LC, Agilent Technologies, Santa Clara, CA, USA) equipped with a vacuum pump, a binary pump mobile phase system, a constant temperature autosampler, and a constant temperature column oven . Chromatographic column: Agilent Zorbax Extend-C18 column (2.1mm×50mm, 1.8μm), detection wavelength: 330nm. Column temperature: 40°C. Injection volume: 1 μL. Flow rate 0.4mL/min, mobile phase: A: 0.1v% formic acid in water, B: methanol. Gradient elution: 0~2min, 0%~30%B; 2~3min, 30%~35%B; 3~4min, 35%~40%B; 4~7min, 40%~50%B; 7~ 8min, 50%~100%B; 8~9min, 100%~100%B; 9~10min, 100%~30%B, equilibration time 5min.
实验结果如下表1,表1中的数据为峰面积。The experimental results are shown in Table 1 below, and the data in Table 1 are peak areas.
表1.Table 1.
1代表新绿原酸、2代表绿原酸、3代表3,5-二咖啡酰奎宁酸、4代表4,5-二咖啡酰奎宁酸。1 represents neochlorogenic acid, 2 represents chlorogenic acid, 3 represents 3,5-dicaffeoylquinic acid, and 4 represents 4,5-dicaffeoylquinic acid.
不同种类吸附剂的固相萃取效果柱状图如图2所示。结果显示,β-环糊精的萃取效果最佳。β-环糊精洗脱下来的溶液为黄绿色且最深。可能由于β-环糊精的分子洞适中使得它能更好地吸附金银花中的活性成分。The histogram of the solid phase extraction effect of different kinds of adsorbents is shown in Fig. 2. The results showed that β-cyclodextrin had the best extraction effect. The β-cyclodextrin eluted solution was yellow-green and darkest. It may be due to the moderate molecular hole of β-cyclodextrin that it can better absorb the active ingredients in honeysuckle.
实施例2Example 2
称取9份金银花药材粉末各25mg分别加入9组研钵中,并称取不同质量(6.25mg、12.5mg、25mg、37.5mg、50mg、62.5mg、75mg、87.5mg、100mg)的β-环糊精,分别加入9组研钵中与金银花药材粉末研磨120s。取9支1mL规格固相萃取小柱,底部均加入筛板,分别用研磨好的粉末填充小柱,填实后顶部均加入筛板。将填好的9支小柱置于固相萃取仪上。取0.5mL甲醇,对小柱逐一进行洗脱。底部分别用9个1.5mL规格离心管收集,后放入离心仪中,13000rpm离心5min。取上层清液装样,用超高效液相色谱仪(UPLC)采样分析。Weigh 25 mg each of 9 honeysuckle medicinal powders and add them into 9 groups of mortars respectively, and weigh β-ring Add dextrin to 9 groups of mortars and grind with honeysuckle powder for 120s. Take nine 1mL solid-phase extraction cartridges, add sieve trays to the bottom, fill the cartridges with ground powder respectively, and add sieve trays to the top after filling. Place the filled 9 small columns on the solid phase extraction apparatus. Take 0.5mL of methanol and elute the small columns one by one. The bottoms were collected with nine 1.5mL centrifuge tubes, and then placed in a centrifuge and centrifuged at 13000rpm for 5min. The supernatant was collected as a sample, and analyzed by ultra-high performance liquid chromatography (UPLC).
实验结果如下表2,表2中的数据为峰面积。The experimental results are shown in Table 2 below, and the data in Table 2 are peak areas.
表2.Table 2.
1代表新绿原酸、2代表绿原酸、3代表3,5-二咖啡酰奎宁酸、4代表4,5-二咖啡酰奎宁酸。1 represents neochlorogenic acid, 2 represents chlorogenic acid, 3 represents 3,5-dicaffeoylquinic acid, and 4 represents 4,5-dicaffeoylquinic acid.
不同的药材与β-环糊精之间质量比例,对基质固相分散萃取效果的影响如图3所示。结果显示,随着β-环糊精用量的增加萃取效果依次增强,但增至75mg后,萃取效果趋于平缓甚至有所下降,所以在后续的实验中选用75mg为最佳的吸附剂用量。可能的原因是,随着吸附剂用量的增加,能够更好地吸附混合固体中的活性成分,但活性成分可吸附的总量有限,吸附剂用量增加至最优值之后,萃取效果趋向平缓,说明活性成分基本已经被吸附剂所吸附。而且过多的吸附剂还会导致活性成分从吸附剂中解吸变得困难,反而使得萃取效果有下降趋势。The influence of the mass ratio between different medicinal materials and β-cyclodextrin on the effect of matrix solid phase dispersion extraction is shown in Figure 3. The results showed that the extraction effect increased sequentially with the increase of the amount of β-cyclodextrin, but after increasing to 75 mg, the extraction effect tended to be flat or even decreased, so 75 mg was selected as the best adsorbent amount in subsequent experiments. The possible reason is that with the increase of the amount of adsorbent, the active ingredient in the mixed solid can be better adsorbed, but the total amount of active ingredient that can be adsorbed is limited. After the amount of adsorbent is increased to the optimal value, the extraction effect tends to be flat. It shows that the active ingredient has basically been adsorbed by the adsorbent. Moreover, too much adsorbent will also make it difficult to desorb the active ingredient from the adsorbent, which will lead to a downward trend in the extraction effect.
实施例3Example 3
称取6份陈皮药材粉末各25mg分别加入6组研钵中,并称取6份75mgβ-环糊精,分别加入6组研钵中与金银花药材粉末研磨不同的时间(60s、80s、100s、120s、140s、160s)。取6支1ml规格的固相萃取小柱,底部均加入筛板,分别用研磨好的粉末填充小柱,填实后顶部均加入筛板。将填好的6支小柱置于固相萃取仪上。取0.5ml的甲醇,注入小柱内,对小柱逐一进行洗脱。底部分别用6个1.5ml规格的离心管收集,放入离子仪中,13000rpm离心5min。取上层清液装样,用超高效液相色谱仪(UPLC)采样分析。Weighed 6 parts of tangerine peel medicinal powder, 25 mg each, and added them to 6 groups of mortars, and weighed 6 parts of 75 mg β-cyclodextrin, respectively, and added them to 6 groups of mortars for different grinding times (60s, 80s, 100s, 60s, 80s, 100s, 120s, 140s, 160s). Take 6 solid-phase extraction columns of 1ml size, add sieve plates to the bottom, fill the columns with ground powder respectively, and add sieve plates to the top after filling. Place the filled 6 small columns on the solid phase extraction apparatus. Take 0.5ml of methanol, inject it into the small column, and elute the small column one by one. The bottom was collected with six 1.5ml centrifuge tubes, placed in an ionizer, and centrifuged at 13000rpm for 5min. The supernatant was collected as a sample, and analyzed by ultra-high performance liquid chromatography (UPLC).
实验结果如下表3,表3中的数据为峰面积。The experimental results are shown in Table 3 below, and the data in Table 3 are peak areas.
表3.table 3.
1代表新绿原酸、2代表绿原酸、3代表3,5-二咖啡酰奎宁酸、4代表4,5-二咖啡酰奎宁酸。1 represents neochlorogenic acid, 2 represents chlorogenic acid, 3 represents 3,5-dicaffeoylquinic acid, and 4 represents 4,5-dicaffeoylquinic acid.
不同研磨时间的基质固相分散萃取效果柱状图见图4。结果显示,随着研磨时间的增加,萃取效果逐渐变大,至最优值120s后,随着研磨时间的增加,萃取效果反而有下降的趋势。可能的原因是,充分的研磨将有助于吸附剂更充分地接触混合固体中的活性成分,从而增加萃取效果。但过量的研磨会使得活性成分被强制挤压在吸附剂中较小、致密的孔径中,使得洗脱变得困难,反而降低了萃取效果。The histogram of matrix solid phase dispersion extraction effect at different grinding times is shown in Figure 4. The results showed that with the increase of grinding time, the extraction effect gradually increased, and after reaching the optimal value of 120s, the extraction effect tended to decline with the increase of grinding time. The possible reason is that sufficient grinding will help the sorbent to more fully contact the active components in the mixed solids, thereby increasing the extraction efficiency. However, excessive grinding will force the active ingredient to be squeezed into the small and dense pore size of the adsorbent, making the elution difficult and reducing the extraction effect.
实施例4Example 4
称取6份金银花药材粉末各25mg分别加入6组研钵中,并称取6份75mgβ-环糊精,分别加入6组研钵中与金银花药材粉末研磨120s。取6支1mL规格固相萃取小柱,底部均加入筛板,分别用研磨好的粉末填充小柱,填实后顶部均加入筛板。将填好的6支小柱置于固相萃取仪上。取0.5mL不同种类的洗脱剂(甲醇、80%甲醇、90%甲醇、乙醇、乙腈、甲醇:乙醇为1∶1),分别注入小柱内,对小柱逐一进行洗脱。底部分别用6个1.5mL规格离心管收集。洗脱结束后,放入离心仪中,13000rpm离心5min。取上层清液装样,用超高效液相色谱仪(UPLC)采样分析。Weigh 6 parts of honeysuckle medicinal powder, 25 mg each, into 6 groups of mortars, and weigh 6 parts of 75 mg β-cyclodextrin, add them into 6 groups of mortars and grind with honeysuckle medicinal powder for 120 s. Take 6 1mL solid-phase extraction cartridges, add sieve trays to the bottom, fill the cartridges with ground powder respectively, and add sieve trays to the top after filling. Place the filled 6 small columns on the solid phase extraction apparatus. Take 0.5mL of different eluents (methanol, 80% methanol, 90% methanol, ethanol, acetonitrile, methanol:ethanol ratio 1:1), inject them into small columns respectively, and elute the small columns one by one. The bottom was collected with six 1.5mL centrifuge tubes respectively. After the elution is completed, put it into a centrifuge and centrifuge at 13000rpm for 5min. The supernatant was collected as a sample, and analyzed by ultra-high performance liquid chromatography (UPLC).
实验结果如下表4,表4中的数据为峰面积。The experimental results are shown in Table 4 below, and the data in Table 4 are peak areas.
表4.Table 4.
1代表新绿原酸、2代表绿原酸、3代表3,5-二咖啡酰奎宁酸、4代表4,5-二咖啡酰奎宁酸。1 represents neochlorogenic acid, 2 represents chlorogenic acid, 3 represents 3,5-dicaffeoylquinic acid, and 4 represents 4,5-dicaffeoylquinic acid.
不同种类洗脱剂的基质固相分散萃取效果柱状图见图5。结果表明,甲醇洗脱效果较其他洗脱液萃取效果好,可能甲醇可以和目标分子之间相互产生氢键作用,相比之下,乙腈一组的实验结果是所有考察组中最差的一组,可能的原因是乙腈对目标分子的溶解能力和与吸附剂相互作用最弱。而80%的甲醇萃取效果最佳可能是由于极性与目标分子最接近。The histogram of matrix solid phase dispersion extraction effect of different eluents is shown in Figure 5. The results show that the methanol elution effect is better than other eluents, and it is possible that methanol can interact with the target molecule to generate hydrogen bonds. In contrast, the experimental results of the acetonitrile group are the worst among all the investigation groups. The possible reason is that acetonitrile has the weakest ability to dissolve target molecules and interact with the adsorbent. The best extraction with 80% methanol may be due to the closest polarity to the target molecule.
日内精密度Intraday precision
称取金银花药材粉末25mg、β-环糊精75mg,加入研钵中研磨120s。取1mL规格固相萃取小柱,底部加入筛板,用研磨好的粉末填充小柱,填实后顶部再加入筛板。将填好的小柱置于固相萃取仪上。取0.5mL80%甲醇水,注入小柱内,对小柱进行洗脱。底部用1.5mL规格离心管收集。洗脱结束后,放入离心仪中,13000rpm离心5min。取上层清液装样,用超高效液相色谱仪(UPLC)采样分析。在同一天内连续进样6次。Weigh 25 mg of honeysuckle powder and 75 mg of β-cyclodextrin, add them into a mortar and grind for 120 seconds. Take a 1mL solid-phase extraction column, add a sieve plate to the bottom, fill the column with ground powder, and add a sieve plate to the top after filling. Place the filled column on the solid phase extraction apparatus. Take 0.5mL of 80% methanol water, inject it into the small column, and elute the small column. Collect the bottom with a 1.5mL centrifuge tube. After the elution is completed, put it into a centrifuge and centrifuge at 13000rpm for 5min. The supernatant was collected as a sample, and analyzed by ultra-high performance liquid chromatography (UPLC). Six consecutive injections were made on the same day.
日间精密度day-to-day precision
称取金银花药材粉末25mg、β-环糊精75mg,加入研钵中研磨120s。取1mL规格固相萃取小柱,底部加入筛板,用研磨好的粉末填充小柱,填实后顶部再加入筛板。将填好的小柱置于固相萃取仪上。取0.5mL80%甲醇水,注入小柱内,对小柱进行洗脱。底部用1.5mL规格离心管收集。洗脱结束后,放入离心仪中,13000rpm离心5min。取上层清液装样,用超高效液相色谱仪(UPLC)采样分析。将该样品连续进样3天,每天2次。Weigh 25 mg of honeysuckle powder and 75 mg of β-cyclodextrin, add them into a mortar and grind for 120 seconds. Take a 1mL solid-phase extraction column, add a sieve plate to the bottom, fill the column with ground powder, and add a sieve plate to the top after filling. Place the filled column on the solid phase extraction apparatus. Take 0.5mL of 80% methanol water, inject it into the small column, and elute the small column. Collect the bottom with a 1.5mL centrifuge tube. After the elution is completed, put it into a centrifuge and centrifuge at 13000rpm for 5min. The supernatant was collected as a sample, and analyzed by ultra-high performance liquid chromatography (UPLC). This sample was injected twice a day for 3 consecutive days.
日内、日间精密度实验结果汇总如下表5:The results of intra-day and inter-day precision experiments are summarized in Table 5 below:
表5table 5
1代表新绿原酸、2代表绿原酸、3代表3,5-二咖啡酰奎宁酸、4代表4,5-二咖啡酰奎宁酸。1 represents neochlorogenic acid, 2 represents chlorogenic acid, 3 represents 3,5-dicaffeoylquinic acid, and 4 represents 4,5-dicaffeoylquinic acid.
重复性考察Repeated inspection
参照下列实验步骤,平行做3组,作为重复性考察。Refer to the following experimental procedures, and do 3 groups in parallel as a repeatability investigation.
称取金银花药材粉末25mg、β-环糊精75mg,加入研钵中研磨120s。取1mL规格固相萃取小柱,底部加入筛板,用研磨好的粉末填充小柱,填实后顶部再加入筛板。将填好的小柱置于固相萃取仪上。取0.5mL80%甲醇水,注入小柱内,对小柱进行洗脱。底部用1.5mL规格离心管收集。洗脱结束后,放入离心仪中,13000rpm离心5min。取上层清液装样,用超高效液相色谱仪(UPLC)采样分析。Weigh 25 mg of honeysuckle powder and 75 mg of β-cyclodextrin, add them into a mortar and grind for 120 seconds. Take a 1mL solid-phase extraction column, add a sieve plate to the bottom, fill the column with ground powder, and add a sieve plate to the top after filling. Place the filled column on the solid phase extraction apparatus. Take 0.5mL of 80% methanol water, inject it into the small column, and elute the small column. Collect the bottom with a 1.5mL centrifuge tube. After the elution is completed, put it into a centrifuge and centrifuge at 13000rpm for 5min. The supernatant was collected as a sample, and analyzed by ultra-high performance liquid chromatography (UPLC).
药材含量测定Determination of medicinal material content
称取金银花药材粉末25mg、β-环糊精75mg,加入研钵中研磨120s。取1mL规格固相萃取小柱,底部加入筛板,用研磨好的粉末填充小柱,填实后顶部再加入筛板。将填好的小柱置于固相萃取仪上。取0.5mL80%甲醇水,注入小柱内,对小柱进行洗脱。底部用1.5mL规格离心管收集。洗脱结束后,放入离心仪中,13000rpm离心5min。取上层清液,即为酚酸类有效成分提取液,用超高效液相色谱仪(UPLC)采样分析。获得提取液的液相色谱图。Weigh 25 mg of honeysuckle powder and 75 mg of β-cyclodextrin, add them into a mortar and grind for 120 seconds. Take a 1mL solid-phase extraction column, add a sieve plate to the bottom, fill the column with ground powder, and add a sieve plate to the top after filling. Place the filled column on the solid phase extraction apparatus. Take 0.5mL of 80% methanol water, inject it into the small column, and elute the small column. Collect the bottom with a 1.5mL centrifuge tube. After the elution is completed, put it into a centrifuge and centrifuge at 13000rpm for 5min. The supernatant was taken, which was the extract of phenolic acid active ingredients, and was sampled and analyzed by ultra-high performance liquid chromatography (UPLC). Obtain a liquid chromatogram of the extract.
图7为酚酸类有效成分提取液的液相色谱图。图中,1、2、3、4分别代表金银花中不同的有效成分,分别为:1:新绿原酸、2:绿原酸、3:3,5-二咖啡酰奎宁酸、4:4,5-二咖啡酰奎宁酸。Fig. 7 is a liquid chromatogram of the extract solution of active ingredients of phenolic acids. In the figure, 1, 2, 3, and 4 represent different active ingredients in honeysuckle, respectively: 1: neochlorogenic acid, 2: chlorogenic acid, 3: 3,5-dicaffeoylquinic acid, 4: 4 , 5-dicaffeoylquinic acid.
以新绿原酸、绿原酸、3,5-二咖啡酰奎宁酸、4,5-二咖啡酰奎宁酸的对照品配制不同浓度的混合对照品溶液,按同样条件用超高效液相色谱检测,获得四者对照品的色谱图,以四者对照品的进样量为横坐标,以四者对照品溶液的色谱图中色谱峰的峰面积为纵坐标,分别制作新绿原酸标准曲线、绿原酸标准曲线、3,5-二咖啡酰奎宁酸标准曲线和4,5-二咖啡酰奎宁酸标准曲线。根据提取液的液相色谱图和标准曲线计算得到金银花药材中新绿原酸、绿原酸、3,5-二咖啡酰奎宁酸、4,5-二咖啡酰奎宁酸的含量。Mixed reference solutions of different concentrations were prepared with reference substances of neochlorogenic acid, chlorogenic acid, 3,5-dicaffeoylquinic acid, and 4,5-dicaffeoylquinic acid, and were tested by ultra-high performance liquid chromatography under the same conditions. Chromatographic detection, obtain the chromatograms of the four reference substances, take the injection volume of the four reference substances as the abscissa, and take the peak area of the chromatographic peak in the chromatogram of the four reference substance solutions as the ordinate, respectively make new chlorogenic acid standards curve, chlorogenic acid standard curve, 3,5-dicaffeoylquinic acid standard curve and 4,5-dicaffeoylquinic acid standard curve. The contents of neochlorogenic acid, chlorogenic acid, 3,5-dicaffeoylquinic acid and 4,5-dicaffeoylquinic acid in honeysuckle were calculated according to the liquid chromatogram of the extract and the standard curve.
新绿原酸、绿原酸、3,5-二咖啡酰奎宁酸、4,5-二咖啡酰奎宁酸浓度均为100μg/mL的金银花对照品溶液的液相色谱图如图6所示,图中,1、2、3、4分别代表金银花中不同的有效成分,分别为:1:新绿原酸、2:绿原酸、3:3,5-二咖啡酰奎宁酸、4:4,5-二咖啡酰奎宁酸。Neochlorogenic acid, chlorogenic acid, 3,5-dicaffeoylquinic acid, and 4,5-dicaffeoylquinic acid are the liquid chromatograms of the Flos Lonicerae reference solution of 100 μg/mL concentration as shown in Figure 6 , in the figure, 1, 2, 3, and 4 represent different active ingredients in honeysuckle, respectively: 1: neochlorogenic acid, 2: chlorogenic acid, 3: 3,5-dicaffeoylquinic acid, 4: 4,5-dicaffeoylquinic acid.
4种成分的标准曲线以及检测限和定量限如下表6所示:The standard curves and limits of detection and limits of quantification of the four components are shown in Table 6 below:
表6.Table 6.
回收率实验Recovery experiment
称取金银花药材粉末25mg、β-环糊精75mg,平行做2组,其中一组加入100μμg/mL的金银花混合对照品50μL,另一组不加金银花混合对照品,两组均加入研钵中研磨120s。分别取2支1mL规格固相萃取小柱,底部加入筛板,用研磨好的粉末填充小柱,填实后顶部再加入筛板。将填好的小柱置于固相萃取仪上。取0.5mL80%甲醇水,分别注入小柱内,对小柱进行逐一洗脱。底部均用1.5mL规格离心管收集。洗脱结束后,放入离心仪中,13000rpm离心5min。取上层清液装样,用超高效液相色谱仪(UPLC)采样分析。Weigh 25 mg of honeysuckle medicinal material powder and 75 mg of β-cyclodextrin, and make 2 groups in parallel. One group adds 50 μL of 100 μg/mL honeysuckle mixed reference substance, and the other group does not add honeysuckle mixed reference substance. Both groups are added to the mortar Grind for 120s. Take two 1mL solid-phase extraction cartridges respectively, add sieve trays to the bottom, fill the cartridges with ground powder, and add sieve trays to the top after filling. Place the filled column on the solid phase extraction apparatus. Take 0.5mL of 80% methanol water and inject them into small columns respectively, and elute the small columns one by one. The bottom was collected with a 1.5mL centrifuge tube. After the elution is completed, put it into a centrifuge and centrifuge at 13000rpm for 5min. The supernatant was collected as a sample, and analyzed by ultra-high performance liquid chromatography (UPLC).
重复性、含量测定、回收率实验结果汇总如下表7:The experimental results of repeatability, content determination and recovery rate are summarized in Table 7 below:
表7Table 7
结果表明,本发明方法的重复性良好,回收率高,检测准确性高。The results show that the method of the invention has good repeatability, high recovery rate and high detection accuracy.
对照例:Comparative example:
按照中国药典中的提取方法为:本品粉末(过四号筛)约0.5g,精密称定,置具塞锥形瓶中,精密加人50%甲醇50ml,称定重量,超声处理(功率250W,频率35kHz)30分钟,放冷,再称定重量,用50%甲醇补足减失的重量,摇匀,滤过,精密量取续滤液5ml,置25ml棕色量瓶中,加50%甲醇至刻度,摇匀,即得。According to the extraction method in the Chinese Pharmacopoeia: about 0.5g of the powder of this product (passed through No. 4 sieve), accurately weighed, put in a stoppered conical flask, accurately add 50% methanol 50ml, weighed, and ultrasonically treated (power 250W, frequency 35kHz) for 30 minutes, let cool, weigh again, make up the lost weight with 50% methanol, shake well, filter, accurately measure 5ml of filtrate, put it in a 25ml brown measuring bottle, add 50% methanol To the scale, shake well, that is.
所得提取液用超高效液相色谱仪(UPLC)采样分析,得到液相色谱图与标准曲线对照,可测得提取液中有效成分相对于金银花药材的含量为新绿原酸2.692mg/g、绿原酸25.05mg/g、3,5-二咖啡酰奎宁酸16.918mg/g、4,5-二咖啡酰奎宁酸2.3375mg/g。而本申请方法制得的提取液中有效成分相对于金银花药材的含量为新绿原酸3.3719mg/g、绿原酸33.3368mg/g、3,5-二咖啡酰奎宁酸20.733mg/g、4,5-二咖啡酰奎宁酸2.7641mg/g,相比药典的方法提取效果明显提高。Gained extract is sampled and analyzed with ultra-high performance liquid chromatography (UPLC), and the liquid chromatogram is compared with the standard curve. It can be measured that the active ingredients in the extract are neochlorogenic acid 2.692mg/g, green Ortho acid 25.05mg/g, 3,5-dicaffeoylquinic acid 16.918mg/g, 4,5-dicaffeoylquinic acid 2.3375mg/g. And the content of active ingredient in the extract liquid that the present application method makes is neochlorogenic acid 3.3719mg/g, chlorogenic acid 33.3368mg/g, 3,5-dicaffeoylquinic acid 20.733mg/g, 4,5-dicaffeoylquinic acid is 2.7641 mg/g, and the extraction effect is significantly improved compared with the pharmacopoeia method.
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510705098.5A CN106610406A (en) | 2015-10-23 | 2015-10-23 | Micro-extraction method of honeysuckle |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510705098.5A CN106610406A (en) | 2015-10-23 | 2015-10-23 | Micro-extraction method of honeysuckle |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106610406A true CN106610406A (en) | 2017-05-03 |
Family
ID=58615190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510705098.5A Pending CN106610406A (en) | 2015-10-23 | 2015-10-23 | Micro-extraction method of honeysuckle |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106610406A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113702549A (en) * | 2021-07-15 | 2021-11-26 | 杭州师范大学 | Miniature extraction method of lotus plumule |
| CN115343390A (en) * | 2022-08-22 | 2022-11-15 | 杭州师范大学 | A method for matrix solid-phase dispersion micro-extraction of effective and harmful components in traditional Chinese medicine |
| CN115684452A (en) * | 2022-10-25 | 2023-02-03 | 杭州师范大学 | Matrix solid-phase dispersion-assisted micro-extraction method of honeysuckle active components in aqueous two-phase system |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4426292A (en) * | 1982-02-19 | 1984-01-17 | Exxon Research And Engineering Co. | Process for selective separation of molecular species from mixtures thereof using cyclodextrins |
| JPH07322823A (en) * | 1991-06-06 | 1995-12-12 | Mercian Corp | Method for improving taste of coffee extract |
| CN1449753A (en) * | 2003-06-02 | 2003-10-22 | 中国科学院上海药物研究所 | Chlorogenic acid and isochlorogenic acid composition and medical use thereof |
| CN1631414A (en) * | 2004-11-15 | 2005-06-29 | 长春今来药业(集团)有限公司 | Medicinal capsule for treating gynecological inflammation and its preparation process |
| CN101237910A (en) * | 2005-08-02 | 2008-08-06 | Wm.雷格利Jr.公司 | Screening method for identifying compositions suitable for treating oral malodor associated with smoking tobacco products |
-
2015
- 2015-10-23 CN CN201510705098.5A patent/CN106610406A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4426292A (en) * | 1982-02-19 | 1984-01-17 | Exxon Research And Engineering Co. | Process for selective separation of molecular species from mixtures thereof using cyclodextrins |
| JPH07322823A (en) * | 1991-06-06 | 1995-12-12 | Mercian Corp | Method for improving taste of coffee extract |
| CN1449753A (en) * | 2003-06-02 | 2003-10-22 | 中国科学院上海药物研究所 | Chlorogenic acid and isochlorogenic acid composition and medical use thereof |
| CN1631414A (en) * | 2004-11-15 | 2005-06-29 | 长春今来药业(集团)有限公司 | Medicinal capsule for treating gynecological inflammation and its preparation process |
| CN101237910A (en) * | 2005-08-02 | 2008-08-06 | Wm.雷格利Jr.公司 | Screening method for identifying compositions suitable for treating oral malodor associated with smoking tobacco products |
Non-Patent Citations (4)
| Title |
|---|
| ALICA ZIAKOVA ET AL: "Matrix solid-phase dispersion for the liquid chromatographic determination of phenolic acids in Melissa officinalis", 《JOURNAL OF CHROMATOGRAPHY A》 * |
| ANDRZEJ L. DAWIDOWICZ ET AL: "Matrix Solid-Phase Dispersion with Sand in Chromatographic Analysis of Essential Oils in Herbs", 《PHYTOCHEM. ANAL.》 * |
| 林丽洋 等: "绿原酸-β-环糊精包合物的制备及验证", 《天津药学》 * |
| 武雪芬 等: "β-环糊精在绿原酸分离中的应用研究", 《河南科学》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113702549A (en) * | 2021-07-15 | 2021-11-26 | 杭州师范大学 | Miniature extraction method of lotus plumule |
| CN115343390A (en) * | 2022-08-22 | 2022-11-15 | 杭州师范大学 | A method for matrix solid-phase dispersion micro-extraction of effective and harmful components in traditional Chinese medicine |
| CN115343390B (en) * | 2022-08-22 | 2023-08-22 | 杭州师范大学 | Method for extracting effective and harmful components in traditional Chinese medicine by matrix solid-phase dispersion |
| CN115684452A (en) * | 2022-10-25 | 2023-02-03 | 杭州师范大学 | Matrix solid-phase dispersion-assisted micro-extraction method of honeysuckle active components in aqueous two-phase system |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104587014B (en) | Method for extracting flavonoid active ingredient from traditional Chinese medicine fructus aurantii | |
| CN104297026B (en) | A kind of method for extracting the flavonoids effective constituent in Chinese medicine dried orange peel | |
| Du et al. | Enrichment and purification of total flavonoid C-glycosides from Abrus mollis extracts with macroporous resins | |
| Zheng et al. | A green and efficient protocol for large‐scale production of glycyrrhizic acid from licorice roots by combination of polyamide and macroporous resin adsorbent chromatography | |
| Zhang et al. | Metal–organic framework assisted matrix solid‐phase dispersion microextraction of saponins using response surface methodology | |
| CN104730171A (en) | Multi-index component content measuring method for roots of common peonies and honeysuckles in Chinese herbal medicine compound preparation | |
| Yu et al. | Simultaneous determination of flavonoids and anthraquinones in honey by using SPE-CE-LIF | |
| CN104614481A (en) | Method for determining antioxidant activity contribution degree of components in Chinese herbal compound | |
| Li et al. | Comparison of different extraction methods of active ingredients of Chinese medicine and natural products | |
| CN106610406A (en) | Micro-extraction method of honeysuckle | |
| CN106610409A (en) | Chitosan filled micro-matrix solid-phase dispersion method | |
| CN104569195B (en) | A method for detecting the content of flavonoid active ingredients in toothpaste containing Chinese medicine Scutellaria baicalensis | |
| CN114994199A (en) | Preparation of a MOF@COF core-shell composite and its application as a solid-phase extraction adsorbent | |
| CN104502485B (en) | The quantitative analysis method of 6 chemical compositions in the compound Chinese medicinal preparation that is medicinal material by rhizoma dioscoreae nipponicae and wilsonii | |
| CN108490083B (en) | Quality detection method of Suhuang cough-relieving capsule | |
| CN103655749B (en) | A kind of magnetic Extraction and enrichment method of Active Constituents in Rhubarb | |
| CN111537647A (en) | Ultra-high performance liquid chromatography analysis method for crimson-cleft-camaldine in flos farfarae | |
| CN103585204B (en) | Thesium granule with high stability and preparation method thereof | |
| CN103822975A (en) | Test method for pulse-activating preparation adopting pilose asiabell root | |
| Zhang et al. | Separation and purification of two flavone glucuronides from Erigeron multiradiatus (Lindl.) Benth with macroporous resins | |
| CN106153810A (en) | A kind of preparation method and application of stem and leaf of Radix Ginseng total saponins reference extract | |
| CN111346195A (en) | A kind of preparation method of grass fruit total flavonoids | |
| CN113092631B (en) | Method for measuring content of phenolic acid in tsaoko | |
| CN112730687B (en) | Method for simultaneously measuring contents of lignans and terpenoids in elecampane pill | |
| CN107664668A (en) | A method for detecting adulterated honey in traditional Chinese medicine honeyed pills |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170503 |